Latanoprostene bunod

Latanoprostene bunod
Clinical data
Trade names	Vyzulta
Other names	BOL-303259-X
ATC code	S01EE06 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name 4-Nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate;
CAS Number	860005-21-6;
PubChem CID	11156438;
DrugBank	DB11660;
UNII	I6393O0922;
KEGG	D10441;
ECHA InfoCard	100.251.571
Chemical and physical data
Formula	C27H41NO8
Molar mass	507.624 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O;
	InChI InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1; Key:LOVMMUBRQUFEAH-UIEAZXIASA-N;

Latanoprostene bunod (trade name Vyzulta) is an ophthalmic drug approved in the United States in 2017 for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.[1][2] It targets the trabecular meshwork directly.[2]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.